EP 3773721 A1 20210217 - STABLE ANTI-CD79B IMMUNOCONJUGATE FORMULATIONS
Title (en)
STABLE ANTI-CD79B IMMUNOCONJUGATE FORMULATIONS
Title (de)
STABILE ANTI-CD79B-IMMUNOKONJUGATFORMULIERUNGEN
Title (fr)
FORMULATIONS D'IMMUNOCONJUGUÉ ANTI-CD79B STABLES
Publication
Application
Priority
- US 201862657185 P 20180413
- US 2019027329 W 20190412
Abstract (en)
[origin: US2019314517A1] The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.
IPC 8 full level
A61K 39/395 (2006.01); A61K 47/26 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC (source: AU CN EP IL KR US)
A61J 1/10 (2013.01 - IL US); A61K 9/0019 (2013.01 - AU CN EP IL KR US); A61K 9/08 (2013.01 - KR); A61K 9/19 (2013.01 - AU CN EP IL KR); A61K 38/05 (2013.01 - AU); A61K 38/08 (2013.01 - CN IL US); A61K 39/39591 (2013.01 - CN EP IL KR); A61K 47/02 (2013.01 - IL US); A61K 47/10 (2013.01 - AU CN EP IL KR US); A61K 47/12 (2013.01 - AU CN KR); A61K 47/14 (2013.01 - IL US); A61K 47/22 (2013.01 - CN IL KR US); A61K 47/26 (2013.01 - AU CN EP IL KR US); A61K 47/34 (2013.01 - IL US); A61K 47/542 (2017.08 - IL US); A61K 47/68031 (2023.08 - AU CN EP IL KR US); A61K 47/6811 (2017.08 - CN IL US); A61K 47/6817 (2017.08 - AU); A61K 47/6849 (2017.08 - AU EP IL KR); A61K 47/6867 (2017.08 - CN EP IL KR); A61K 47/6873 (2017.08 - IL US); A61K 47/6889 (2017.08 - AU CN EP IL KR); A61P 35/00 (2018.01 - AU CN KR); A61P 35/02 (2018.01 - CN); C07K 16/2803 (2013.01 - CN EP IL KR US); A61J 1/10 (2013.01 - EP); A61K 2039/505 (2013.01 - AU KR); A61K 2121/00 (2013.01 - AU); A61K 2300/00 (2013.01 - AU); C07K 2317/24 (2013.01 - CN IL KR US); C07K 2317/56 (2013.01 - CN IL KR US)
C-Set (source: CN)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
US 11648317 B2 20230516; US 2019314517 A1 20191017; AR 114780 A1 20201014; AU 2019252941 A1 20201119; BR 112020020802 A2 20210112; CA 3095186 A1 20191017; CL 2020002624 A1 20210129; CL 2021001956 A1 20220204; CN 112040981 A 20201204; CN 113384711 A 20210914; CR 20200550 A 20201215; EP 3773721 A1 20210217; EP 3773721 A4 20220126; IL 277943 A 20201130; JP 2019206514 A 20191205; JP 2020158505 A 20201001; JP 2022036932 A 20220308; JP 6761506 B2 20200923; JP 6965395 B2 20211110; KR 20210003147 A 20210111; MX 2020010729 A 20210309; MX 2022014457 A 20221208; PE 20201503 A1 20201229; TW 202011994 A 20200401; TW 202344272 A 20231116; TW I811335 B 20230811; UA 128064 C2 20240327; WO 2019200322 A1 20191017
DOCDB simple family (application)
US 201916383478 A 20190412; AR P190100971 A 20190412; AU 2019252941 A 20190412; BR 112020020802 A 20190412; CA 3095186 A 20190412; CL 2020002624 A 20201009; CL 2021001956 A 20210723; CN 201980025490 A 20190412; CN 202110524346 A 20190412; CR 20200550 A 20190412; EP 19785369 A 20190412; IL 27794320 A 20201011; JP 2019076133 A 20190412; JP 2020079093 A 20200428; JP 2021171589 A 20211020; KR 20207032399 A 20190412; MX 2020010729 A 20190412; MX 2022014457 A 20201009; PE 2020001583 A 20190412; TW 108112935 A 20190412; TW 112126392 A 20190412; UA A202006479 A 20190412; US 2019027329 W 20190412